U.S., July 25 -- ClinicalTrials.gov registry received information related to the study (NCT07083960) titled 'OM336 in Autoimmune Cytopenias' on July 09.
Brief Summary: An early-phase clinical trial evaluating the safety, tolerability, and pharmacokinetics of subcutaneously dosed OM336 in adult participants with autoimmune cytopenias.
Study Start Date: Aug., 2025
Study Type: INTERVENTIONAL
Condition:
AIHA - Warm Autoimmune Hemolytic Anemia
AIHA - Cold Autoimmune Hemolytic Anemia
ITP - Immune Thrombocytopenia
Intervention:
DRUG: OM336
OM336 is an engineered bispecific antibody directed against BCMA and CD3
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Ouro Medicines
Disclaimer: Curated by HT Syndication....